ADPEN Laboratories

The Analytical Partner You Trust

  • ABOUT ADPEN
    • CORONAVIRUS UPDATE:
    • Our Staff
    • Our Facilities
    • Our Instrumentation
  • CONTACT ADPEN
    • Request Info or Quote
  • TEST REQUEST FORMS
  • RESOURCES
    • Analytical Services and Testing Brochures
    • Career Opportunities
    • Industry Guidance Documents
    • Terms and Conditions
  • AGROSCIENCES
    • ANALYTICAL TESTING
    • ECOTOX
    • 5-BATCH ANALYSIS
    • PRODUCT CHEMISTRY
  • PHARMACEUTICALS
    • CONTRACT FORMULATION AND MANUFACTURING
    • PHARMACEUTICAL TESTING
    • NITROSAMINE IMPURITIES IN PHARMACEUTICALS
  • FOOD SAFETY
    • NUTRITIONALS
    • FOOD SAFETY TESTING
  • ANIMAL HEALTH
You are here: Home / ALL NEWS / Analytical Testing News & Updates | ADPEN Laboratories / FDA Issues Guidance on Bioequivalence Studies

FDA Issues Guidance on Bioequivalence Studies

July 7, 2011 By Steven Perez

This past May, FDA issued a new guidance for industry concerning the submission of summary bioequivalence data for abbreviated new drug applications (ANDAs). The guidance is meant to clarify the requirements for the submission of bioequivalence data that were published in 2009 (1). Federal regulations require that all bioequivalence studies performed for a given agent be submitted as part of the ANDA, regardless of whether the study confirms that the product is equivalent to the reference listed drug (RLD).

FDA believes that review of both positive and negative data may be “important in our determination of whether a product is bioequivalent to the RLD and are relevant to our evaluation of generic products in general,” according to the guidance. “These data will increase our understanding of generic drug development and how changes in components and composition may affect formulation performance, as well as promote further development of science-based bioequivalence policies,” says the guidance.

Read the article at Pharmatech.

Filed Under: Analytical Testing News & Updates | ADPEN Laboratories, Pharmaceutical Links Tagged With: ANDA, bioequivalence, drug, FDA, generic, guidance, pharmaceutical, RLD, Testing

ISO/IEC 17025 ACCREDITED

ISO/IEC 17025 is a company level accreditation based on a standard published by the International Organization for Standardization (ISO) titled “General requirements for the competence of testing and calibration laboratories”. ISO/IEC 17025 is a general umbrella term used to refer to the specific standard; the current version of this standard is ISO/IEC 17025:2017. The standard contains two main sections: management requirements (primarily related to the operation and effectiveness of the quality management system within the laboratory) and technical requirements (primarily related to the competence of staff and calibration of equipment). The standard also gives requirements related to quality management such as document control and corrective action. This standard is the basis for accreditation from an accrediting body.

ADPEN has also been inspected by the US-EPA and US-FDA multiple times with no observations.

Agroscience Links

  • 5-Batch Analytical Services
  • Analytical Testing Brochure
  • Pesticide Residue Analytical Services

Let’s Network!

Follow @AdpenLabs

RSS USEPA- Agriculture News

What Our Clients Say About ADPEN

“Special thanks to the ADPEN team for striving to get the analysis we need in a timely manner.” -R.W.

Get in Touch With Us

ADPEN Laboratories, Inc.
11757 Central Parkway
Jacksonville, FL 32224 USA

Phone: 1.904.645.9169
Fax: (904) 641-8423
Contact Form

Copyright © 2021 · Enterprise Pro Theme on Genesis Framework · WordPress · Log in